An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model.
The Zika virus (ZIKV) outbreak in the Americas and South Pacific poses a significant burden on human health because of ZIKV's neurotropic effects in the course of fetal development. Vaccine candidates against ZIKV are coming online, but immunological tools to study anti-ZIKV responses in preclinical models, particularly T cell responses, remain sparse. We deployed RNA nanoparticle technology to create a vaccine candidate that elicited ZIKV E protein-specific IgG responses in C57BL/6 mice as assayed by ELISA. Using this tool, we identified a unique H-2Db-restricted epitope to which there was a CD8+T cell response in mice immunized with our modified dendrimer-based RNA nanoparticle vaccine. These results demonstrate that this approach can be used to evaluate new candidate antigens and identify immune correlates without the use of live virus.
Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, MA, 02142, USA.|The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02142, USA.
Jasdave S
JS
Chahal
Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, MA, 02142, USA.
Tao
0000-0001-8129-8635
T
Fang
Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, MA, 02142, USA.
Andrew W
AW
Woodham
The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02142, USA.
Omar F
OF
Khan
Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, MA, 02142, USA.
Jingjing
J
Ling
The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02142, USA.
Daniel G
DG
Anderson
Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, MA, 02142, USA. hidde.ploegh@childrens.harvard.edu.|Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, 02115, USA. hidde.ploegh@childrens.harvard.edu.
Hidde L
HL
Ploegh
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D050091:Dendrimers / Q000008:administration & dosage / Q000302:isolation & purification; D004797:Enzyme-Linked Immunosorbent Assay; D018984:Epitopes, T-Lymphocyte / Q000276:immunology; D007074:Immunoglobulin G / Q000097:blood; D008810:Mice, Inbred C57BL; D053758:Nanoparticles / Q000008:administration & dosage; D012367:RNA, Viral / Q000008:administration & dosage / Q000276:immunology* / Q000302:isolation & purification; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology* / Q000302:isolation & purification; D000071244:Zika Virus / Q000276:immunology*; D000071243:Zika Virus Infection / Q000517:prevention & control*
D000914:Antibodies, Viral; D050091:Dendrimers; D018984:Epitopes, T-Lymphocyte; D007074:Immunoglobulin G; D012367:RNA, Viral; D014765:Viral Vaccines